Ness Ziona, Israel, Tuesday, February 7, 06 --- Foamix Ltd. announced today the issuance of two separate patents for its OilGel™ technology. Patent No. 6,994,863 was issued to Foamix for OilGel™ on February 7, 2006 by The United States Patent and Trademark Office (USPTO). The patent, titled "Pharmaceutical and Cosmetic Carrier or Composition for Topical Application" covers the Company's methods of treatment of various disorders, using the OilGel™ technology. The second patent, number 782515 was concurrently issued to Foamix for its OilGel™ by the Australian Patent Office. The patent, titled “Pharmaceutical and Cosmetic Carrier or Composition for Topical Application” covers composition and the use of OilGel™ as a treatment for dermatological and ophthalmic diseases. The term of the Australian patent is through January 10, 2021.

OilGel™ is a delivery system of medicated actives for the treatment of skin and eye diseases. It transforms a semi-solid into a liquid instantly after application and as such does NOT create a sticky feeling or blurred vision.

“We are excited to have received the latest in a series of U.S. patents for this technology. We are equally thrilled to have opened the door in Australia. This is indicative of Foamix’s ongoing effort to develop its technology for use worldwide,” said Foamix CEO Dr. Dov Tamarkin.

In line with the receipt of the U.S. and Australian patents, Foamix is dedicating additional resources to developing its OilGel™ platform and to accelerating the development and launch of  OilGel™ products.

About Foamix (www.foamix.co.il)

Headquartered in Ness Ziona, Israel, Foamix Ltd. develops alcohol-free, non-flammable, stable foam products for prescription, Over-the-Counter and cosmetic uses. Foamix’s state-of-the-art foams provide controlled delivery of a variety of active ingredients. They are also able to enhance intradermal delivery of actives, for optimal effect. The Company’s development capabilities range from initial development of foam formulations to scale-up, GMP manufacturing and clinical supplies. The Company was founded in January 2003 by CEO Dr. Dov Tamarkin, COO Mr. Meir Eini and Chief Technology Officer Dr. Doron Friedman. Foamix Ltd. is a privately held company, whose business model is based on partnering with leading pharma and cosmetics companies to develop products utilizing its proprietary foam and OilGel™ technologies.

For additional information: Marjie Hadad, Media Liaison, Marjie@foamix.co.il or +972-54-536-5220